FDA approves Daiichi Sankyo's new first-line AML drug quizartinib with boxed warning for heart disorders
Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option for the first time, thanks to the FDA’s approval of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
